ASCO 2024 – Krazati looks more similar than different to Lumakras
Meanwhile, Lilly gets in on the next-gen KRAS action.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
The month ahead: May’s remaining events
ASCO is fast approaching, but in the meantime Olema will have an important readout.
Merus’s big bispecific test approaches
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Bristol backs out of BET inhibition
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
